Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2016 Jun;99(6):642-50.
doi: 10.1002/cpt.319. Epub 2016 Jan 12.

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD

Affiliations

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD

J T Brown et al. Clin Pharmacol Ther.2016 Jun.

Abstract

The effect of CYP2D6 genotype on the dose-exposure relationship for atomoxetine has not been well characterized in children. Children 6-17 years of age diagnosed with attention-deficit hyperactivity disorder (ADHD) were stratified by CYP2D6 genotype into groups with 0 (poor metabolizers [PMs], n = 4), 0.5 (intermediate metabolizers [IMs], n = 3), one (extensive metabolizer [EM]1, n = 8) or two (EM2, n = 8) functional alleles and administered a single 0.5 mg/kg oral dose of atomoxetine (ATX). Plasma and urine samples were collected for 24 (IM, EM1, and EM2) or 72 hours (PMs). Dose-corrected ATX systemic exposure (area under the curve [AUC]0-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4 ± 2.7 μM*h in EM2s to 5.8 ± 1.7 μM*h, 16.3 ± 2.9 μM*h, and 50.2 ± 7.3 μM*h in EM1s, IMs, and PMs, respectively (P < 0.0001). Simulated steady state profiles at the maximum US Food and Drug Administration (FDA)-recommended dose suggest that most patients are unlikely to attain adequate ATX exposures. These data support the need for individualized dosing strategies for more effective use of the medication.

© 2015 American Society for Clinical Pharmacology and Therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Effect ofCYP2D6 genotype on mean ± SD plasma concentration time profiles for ATX (panel A), 4-OH-ATX (panel B), and itsN-desmethyl metabolite NDA (panel C). In panel B, lines of best fit are provided for total 4-OH-ATX (non-conjugated plus glucuronide conjugate), whereas the concentration-time profiles for the therapeutically active, non-conjugated form are presented within the shaded area. Concentrations of non-conjugated 4-OH-ATX are considerably lower than ATX concentrations at all time points, and do not contribute to any appreciable extent to total therapeutically active drug in any genotype group.
Figure 2
Figure 2
Association betweenCYP2D6 genotype expressed as activity score and total ATX systemic exposure (AUC0-∞). As a single capsule of the available dosage forms was administered to provide a dose at or near the recommended starting dose of 0.5 mg/kg, the actual dose administered ranged from 0.34–0.59 mg/kg, and AUC0-∞ data were normalized to a 0.5 mg/kg dose. The one participant with aCYP2D6 activity score of 3 (three functional alleles) included in the EM2 group is designated by the black symbol.
Figure 3
Figure 3
Urinary recovery of ATX and metabolites. The percentage of the administered dose recovered in 24 h (IM, EM1, EM2) or 72 h (PM) urine collections as ATX (panel A), NDA (panel B) and carboxy metabolites, products of subsequent biotransformation of initial 2-methylhydroxylation (panel C), is presented as a function of the percentage of the administered dose recovered as 4-OH-ATX. Recovery exceeded 100% of the dose in two subjects (~105%). 4-OH-ATX was the most abundant single metabolite recovered in all CYP2D6 genotype groups, but the hydroxycarboxy products of initial 2-methylhydroxylation constituted a considerably larger proportion of overall ATX biotransformation in the PM group. Individual data points are color-coded by genotype (PM, red; IM, yellow; EM1, green; EM2, blue), and the size of the circles represent the apparent oral clearance relative to the largest apparent oral clearance in an individual with three functional CYP2D6 alleles (black symbol); NDA was not detected in the urine of this participant. The extremely small size of the PM data points relative to the reference demonstrates that the increased contribution of 2-hydroxylation in PMs does not “compensate” for the absence of CYP2D6 activity.
Figure 4
Figure 4
Simulated atomoxetine plasma concentration-time profiles for each study participant over the first 10 days of treatment with the current maximum FDA-recommended dose of 1.4 mg/kg up to 100 mg/d. A. The dashed line represents the threshold for therapeutic benefit proposed by Michelson et al. Plasma concentration profiles are color-coded for the genotype-stratified groups: PM (red), IM (yellow), EM1 (green) and EM2 (blue). The one participant with a CYP2D6 activity score of 3 (three functional alleles) included in the EM2 group is represented by the black profile. B. The gray shaded area in panel A is expanded to demonstrate that at steady state, only five study participants would exceed the proposed 800 ng/ml (~3.1 μM) threshold for any appreciable period of time under current FDA-approved dosing guidelines. Ordinate axes are provided for interconversion of ng/ml and μM units.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30:319–23. - PubMed
    1. Sauer JM, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31:98–107. - PubMed
    1. Witcher JW, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13:53–63. - PubMed
    1. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242–51. - PubMed
    1. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234–42. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp